APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oligodendroglioma Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Oligodendroglioma Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174018580322 December 2025197 pages

Choose your research edition.

Industry ResearchOligodendroglioma Treatment Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Oligodendroglioma Treatment Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Oligodendroglioma Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oligodendroglioma Treatment Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Oligodendroglioma Treatment Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Oligodendroglioma Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Oligodendroglioma Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oligodendroglioma Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oligodendroglioma Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Oligodendroglioma Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oligodendroglioma Treatment include Novartis AG, F. Hoffmann-La Roche Ltd, Eli Lilly and Co, Pfizer Inc, Tocagen Inc, Northwest Biotherapeutics Inc, Millennium Pharmaceuticals Inc, Leadiant Biosciences Inc and Ipsen SA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oligodendroglioma Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oligodendroglioma Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oligodendroglioma Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oligodendroglioma Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Oligodendroglioma Treatment Segment by Company

Novartis AG

F. Hoffmann-La Roche Ltd

Eli Lilly and Co

Pfizer Inc

Tocagen Inc

Northwest Biotherapeutics Inc

Millennium Pharmaceuticals Inc

Leadiant Biosciences Inc

Ipsen SA

Immatics Biotechnologies GmbH

Celldex Therapeutics Inc

Cavion LLC

Bristol-Myers Squibb Co

Boehringer Ingelheim GmbH

AngioChem Inc

Oligodendroglioma Treatment Segment by Type

Dasatinib

Bevacizumab

IMA-950

DCVax-L

CDX-1401

Alisertib

Others

Oligodendroglioma Treatment Segment by Application

ASCs

Hospital

Clinic

Oligodendroglioma Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligodendroglioma Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oligodendroglioma Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligodendroglioma Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oligodendroglioma Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Oligodendroglioma Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Oligodendroglioma Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Oligodendroglioma Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Oligodendroglioma Treatment Industry Trends Table 2. Oligodendroglioma Treatment Industry Drivers Table 3. Oligodendroglioma Treatment Industry Opportunities and Challenges Table 4. Oligodendroglioma Treatment Industry Restraints Table 5. Global Oligodendroglioma Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Oligodendroglioma Treatment Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Oligodendroglioma Treatment Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Oligodendroglioma Treatment Sales Market Share by Manufacturers Table 9. Global Oligodendroglioma Treatment Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Oligodendroglioma Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Oligodendroglioma Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Oligodendroglioma Treatment Manufacturers, Product Type & Application Table 13. Global Oligodendroglioma Treatment Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Oligodendroglioma Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Dasatinib Table 17. Major Manufacturers of Bevacizumab Table 18. Major Manufacturers of IMA-950 Table 19. Major Manufacturers of DCVax-L Table 20. Major Manufacturers of CDX-1401 Table 21. Major Manufacturers of Alisertib Table 22. Major Manufacturers of Others Table 23. Global Oligodendroglioma Treatment Sales by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Oligodendroglioma Treatment Sales by Type (2021-2026) & (k units) Table 25. Global Oligodendroglioma Treatment Sales by Type (2027-2032) & (k units) Table 26. Global Oligodendroglioma Treatment Sales Market Share by Type (2021-2026) Table 27. Global Oligodendroglioma Treatment Sales Market Share by Type (2027-2032) Table 28. Global Oligodendroglioma Treatment Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 29. Global Oligodendroglioma Treatment Revenue by Type (2021-2026) & (k units) Table 30. Global Oligodendroglioma Treatment Revenue by Type (2027-2032) & (k units) Table 31. Global Oligodendroglioma Treatment Revenue Market Share by Type (2021-2026) Table 32. Global Oligodendroglioma Treatment Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of ASCs Table 34. Major Manufacturers of Hospital Table 35. Major Manufacturers of Clinic Table 36. Global Oligodendroglioma Treatment Sales by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Oligodendroglioma Treatment Sales by Application (2021-2026) & (k units) Table 38. Global Oligodendroglioma Treatment Sales by Application (2027-2032) & (k units) Table 39. Global Oligodendroglioma Treatment Sales Market Share by Application (2021-2026) Table 40. Global Oligodendroglioma Treatment Sales Market Share by Application (2027-2032) Table 41. Global Oligodendroglioma Treatment Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 42. Global Oligodendroglioma Treatment Revenue by Application (2021-2026) & (k units) Table 43. Global Oligodendroglioma Treatment Revenue by Application (2027-2032) & (k units) Table 44. Global Oligodendroglioma Treatment Revenue Market Share by Application (2021-2026) Table 45. Global Oligodendroglioma Treatment Revenue Market Share by Application (2027-2032) Table 46. Global Oligodendroglioma Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Oligodendroglioma Treatment Sales by Region (2021-2026) & (k units) Table 48. Global Oligodendroglioma Treatment Sales Market Share by Region (2021-2026) Table 49. Global Oligodendroglioma Treatment Sales Forecasted by Region (2027-2032) & (k units) Table 50. Global Oligodendroglioma Treatment Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Oligodendroglioma Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. North America Oligodendroglioma Treatment Sales by Country (2021-2026) & (k units) Table 53. North America Oligodendroglioma Treatment Sales by Country (2027-2032) & (k units) Table 54. Europe Oligodendroglioma Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Europe Oligodendroglioma Treatment Sales by Country (2021-2026) & (k units) Table 56. Europe Oligodendroglioma Treatment Sales by Country (2027-2032) & (k units) Table 57. Asia Pacific Oligodendroglioma Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Asia Pacific Oligodendroglioma Treatment Sales by Country (2021-2026) & (k units) Table 59. Asia Pacific Oligodendroglioma Treatment Sales by Country (2027-2032) & (k units) Table 60. South America, Middle East and Africa Oligodendroglioma Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 61. South America, Middle East and Africa Oligodendroglioma Treatment Sales by Country (2021-2026) & (k units) Table 62. South America, Middle East and Africa Oligodendroglioma Treatment Sales by Country (2027-2032) & (k units) Table 63. Global Oligodendroglioma Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Oligodendroglioma Treatment Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Oligodendroglioma Treatment Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Oligodendroglioma Treatment Revenue Market Share by Region (2021-2026) Table 67. Global Oligodendroglioma Treatment Revenue Market Share by Region (2027-2032) Table 68. Novartis AG Company Information Table 69. Novartis AG Business Overview Table 70. Novartis AG Oligodendroglioma Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Novartis AG Oligodendroglioma Treatment Product Portfolio Table 72. Novartis AG Recent Development Table 73. F. Hoffmann-La Roche Ltd Company Information Table 74. F. Hoffmann-La Roche Ltd Business Overview Table 75. F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Product Portfolio Table 77. F. Hoffmann-La Roche Ltd Recent Development Table 78. Eli Lilly and Co Company Information Table 79. Eli Lilly and Co Business Overview Table 80. Eli Lilly and Co Oligodendroglioma Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Eli Lilly and Co Oligodendroglioma Treatment Product Portfolio Table 82. Eli Lilly and Co Recent Development Table 83. Pfizer Inc Company Information Table 84. Pfizer Inc Business Overview Table 85. Pfizer Inc Oligodendroglioma Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Pfizer Inc Oligodendroglioma Treatment Product Portfolio Table 87. Pfizer Inc Recent Development Table 88. Tocagen Inc Company Information Table 89. Tocagen Inc Business Overview Table 90. Tocagen Inc Oligodendroglioma Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Tocagen Inc Oligodendroglioma Treatment Product Portfolio Table 92. Tocagen Inc Recent Development Table 93. Northwest Biotherapeutics Inc Company Information Table 94. Northwest Biotherapeutics Inc Business Overview Table 95. Northwest Biotherapeutics Inc Oligodendroglioma Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Northwest Biotherapeutics Inc Oligodendroglioma Treatment Product Portfolio Table 97. Northwest Biotherapeutics Inc Recent Development Table 98. Millennium Pharmaceuticals Inc Company Information Table 99. Millennium Pharmaceuticals Inc Business Overview Table 100. Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Product Portfolio Table 102. Millennium Pharmaceuticals Inc Recent Development Table 103. Leadiant Biosciences Inc Company Information Table 104. Leadiant Biosciences Inc Business Overview Table 105. Leadiant Biosciences Inc Oligodendroglioma Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Leadiant Biosciences Inc Oligodendroglioma Treatment Product Portfolio Table 107. Leadiant Biosciences Inc Recent Development Table 108. Ipsen SA Company Information Table 109. Ipsen SA Business Overview Table 110. Ipsen SA Oligodendroglioma Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Ipsen SA Oligodendroglioma Treatment Product Portfolio Table 112. Ipsen SA Recent Development Table 113. Immatics Biotechnologies GmbH Company Information Table 114. Immatics Biotechnologies GmbH Business Overview Table 115. Immatics Biotechnologies GmbH Oligodendroglioma Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Immatics Biotechnologies GmbH Oligodendroglioma Treatment Product Portfolio Table 117. Immatics Biotechnologies GmbH Recent Development Table 118. Celldex Therapeutics Inc Company Information Table 119. Celldex Therapeutics Inc Business Overview Table 120. Celldex Therapeutics Inc Oligodendroglioma Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Celldex Therapeutics Inc Oligodendroglioma Treatment Product Portfolio Table 122. Celldex Therapeutics Inc Recent Development Table 123. Cavion LLC Company Information Table 124. Cavion LLC Business Overview Table 125. Cavion LLC Oligodendroglioma Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Cavion LLC Oligodendroglioma Treatment Product Portfolio Table 127. Cavion LLC Recent Development Table 128. Bristol-Myers Squibb Co Company Information Table 129. Bristol-Myers Squibb Co Business Overview Table 130. Bristol-Myers Squibb Co Oligodendroglioma Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Bristol-Myers Squibb Co Oligodendroglioma Treatment Product Portfolio Table 132. Bristol-Myers Squibb Co Recent Development Table 133. Boehringer Ingelheim GmbH Company Information Table 134. Boehringer Ingelheim GmbH Business Overview Table 135. Boehringer Ingelheim GmbH Oligodendroglioma Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Boehringer Ingelheim GmbH Oligodendroglioma Treatment Product Portfolio Table 137. Boehringer Ingelheim GmbH Recent Development Table 138. AngioChem Inc Company Information Table 139. AngioChem Inc Business Overview Table 140. AngioChem Inc Oligodendroglioma Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. AngioChem Inc Oligodendroglioma Treatment Product Portfolio Table 142. AngioChem Inc Recent Development Table 143. Key Raw Materials Table 144. Raw Materials Key Suppliers Table 145. Oligodendroglioma Treatment Distributors List Table 146. Oligodendroglioma Treatment Customers List Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Oligodendroglioma Treatment Product Image Figure 2. Global Oligodendroglioma Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oligodendroglioma Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Oligodendroglioma Treatment Sales (2021-2032) & (k units) Figure 5. Global Oligodendroglioma Treatment Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Oligodendroglioma Treatment Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Dasatinib Image Figure 9. Bevacizumab Image Figure 10. IMA-950 Image Figure 11. DCVax-L Image Figure 12. CDX-1401 Image Figure 13. Alisertib Image Figure 14. Others Image Figure 15. Global Oligodendroglioma Treatment Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Oligodendroglioma Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global Oligodendroglioma Treatment Sales Market Share by Type (2021-2032) Figure 18. Global Oligodendroglioma Treatment Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Oligodendroglioma Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Oligodendroglioma Treatment Revenue Market Share by Type (2021-2032) Figure 21. ASCs Image Figure 22. Hospital Image Figure 23. Clinic Image Figure 24. Global Oligodendroglioma Treatment Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Oligodendroglioma Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Oligodendroglioma Treatment Sales Market Share by Application (2021-2032) Figure 27. Global Oligodendroglioma Treatment Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 28. Global Oligodendroglioma Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Oligodendroglioma Treatment Revenue Market Share by Application (2021-2032) Figure 30. North America Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 31. North America Oligodendroglioma Treatment Sales Market Share by Country (2021-2032) Figure 32. U.S. Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 33. Canada Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 34. Mexico Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 36. Europe Oligodendroglioma Treatment Sales Market Share by Country (2021-2032) Figure 37. Germany Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 38. France Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 39. U.K. Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 40. Italy Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 41. Netherlands Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 43. Asia Pacific Oligodendroglioma Treatment Sales Market Share by Country (2021-2032) Figure 44. China Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 45. Japan Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 46. South Korea Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 47. Southeast Asia Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 48. India Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 49. Australia Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 51. South America, Middle East and Africa Oligodendroglioma Treatment Sales Market Share by Country (2021-2032) Figure 52. Brazil Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 53. South Africa Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 54. Saudi Arabia Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 55. Turkey Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 56. Argentina Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 57. UAE Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 58. Egypt Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 59. Chile Oligodendroglioma Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 60. Global Oligodendroglioma Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Oligodendroglioma Treatment Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Oligodendroglioma Treatment Revenue (2021-2032) & (US$ Million) Figure 63. North America Oligodendroglioma Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Oligodendroglioma Treatment Revenue (2021-2032) & (US$ Million) Figure 65. Europe Oligodendroglioma Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Oligodendroglioma Treatment Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Oligodendroglioma Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Oligodendroglioma Treatment Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Oligodendroglioma Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Oligodendroglioma Treatment Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Oligodendroglioma Treatment Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Dasatinib
  • Bevacizumab
  • IMA-950
  • DCVax-L
  • CDX-1401
  • Alisertib
  • Others
Applications
  • ASCs
  • Hospital
  • Clinic
Companies covered
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Co
  • Pfizer Inc
  • Tocagen Inc
  • Northwest Biotherapeutics Inc
  • Millennium Pharmaceuticals Inc
  • Leadiant Biosciences Inc
  • Ipsen SA
  • Immatics Biotechnologies GmbH
  • Celldex Therapeutics Inc
  • Cavion LLC
  • Bristol-Myers Squibb Co
  • Boehringer Ingelheim GmbH
  • AngioChem Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oligodendroglioma Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oligodendroglioma Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Oligodendroglioma Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Oligodendroglioma Treatment Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Oligodendroglioma Treatment Market Dynamics
  1. 2.1 Oligodendroglioma Treatment Industry Trends
  2. 2.2 Oligodendroglioma Treatment Industry Drivers
  3. 2.3 Oligodendroglioma Treatment Industry Opportunities and Challenges
  4. 2.4 Oligodendroglioma Treatment Industry Restraints
3 Oligodendroglioma Treatment Market by Manufacturers
  1. 3.1 Global Oligodendroglioma Treatment Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Oligodendroglioma Treatment Sales by Manufacturers (2021-2026)
  3. 3.3 Global Oligodendroglioma Treatment Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Oligodendroglioma Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Oligodendroglioma Treatment Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Oligodendroglioma Treatment Manufacturers, Product Type & Application
  7. 3.7 Global Oligodendroglioma Treatment Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Oligodendroglioma Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Oligodendroglioma Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Oligodendroglioma Treatment Tier 1, Tier 2, and Tier 3
4 Oligodendroglioma Treatment Market by Type
  1. 4.1 Oligodendroglioma Treatment Type Introduction
  2. 4.1.1 Dasatinib
  3. 4.1.2 Bevacizumab
  4. 4.1.3 IMA-950
  5. 4.1.4 DCVax-L
  6. 4.1.5 CDX-1401
  7. 4.1.6 Alisertib
  8. 4.1.7 Others
  9. 4.2 Global Oligodendroglioma Treatment Sales by Type
  10. 4.2.1 Global Oligodendroglioma Treatment Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Oligodendroglioma Treatment Sales by Type (2021-2032)
  12. 4.2.3 Global Oligodendroglioma Treatment Sales Market Share by Type (2021-2032)
  13. 4.3 Global Oligodendroglioma Treatment Revenue by Type
  14. 4.3.1 Global Oligodendroglioma Treatment Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Oligodendroglioma Treatment Revenue by Type (2021-2032)
  16. 4.3.3 Global Oligodendroglioma Treatment Revenue Market Share by Type (2021-2032)
5 Oligodendroglioma Treatment Market by Application
  1. 5.1 Oligodendroglioma Treatment Application Introduction
  2. 5.1.1 ASCs
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.2 Global Oligodendroglioma Treatment Sales by Application
  6. 5.2.1 Global Oligodendroglioma Treatment Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oligodendroglioma Treatment Sales by Application (2021-2032)
  8. 5.2.3 Global Oligodendroglioma Treatment Sales Market Share by Application (2021-2032)
  9. 5.3 Global Oligodendroglioma Treatment Revenue by Application
  10. 5.3.1 Global Oligodendroglioma Treatment Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Oligodendroglioma Treatment Revenue by Application (2021-2032)
  12. 5.3.3 Global Oligodendroglioma Treatment Revenue Market Share by Application (2021-2032)
6 Global Oligodendroglioma Treatment Sales by Region
  1. 6.1 Global Oligodendroglioma Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oligodendroglioma Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Oligodendroglioma Treatment Sales by Region (2021-2026)
  4. 6.2.2 Global Oligodendroglioma Treatment Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oligodendroglioma Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Oligodendroglioma Treatment Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Oligodendroglioma Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Oligodendroglioma Treatment Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Oligodendroglioma Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Oligodendroglioma Treatment Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Oligodendroglioma Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Oligodendroglioma Treatment Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Oligodendroglioma Treatment Revenue by Region
  1. 7.1 Global Oligodendroglioma Treatment Revenue by Region
  2. 7.1.1 Global Oligodendroglioma Treatment Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Oligodendroglioma Treatment Revenue by Region (2021-2026)
  4. 7.1.3 Global Oligodendroglioma Treatment Revenue by Region (2027-2032)
  5. 7.1.4 Global Oligodendroglioma Treatment Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Oligodendroglioma Treatment Revenue (2021-2032)
  8. 7.2.2 North America Oligodendroglioma Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Oligodendroglioma Treatment Revenue (2021-2032)
  11. 7.3.2 Europe Oligodendroglioma Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Oligodendroglioma Treatment Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Oligodendroglioma Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Oligodendroglioma Treatment Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Oligodendroglioma Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Oligodendroglioma Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Oligodendroglioma Treatment Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 F. Hoffmann-La Roche Ltd
  8. 8.2.1 F. Hoffmann-La Roche Ltd Company Information
  9. 8.2.2 F. Hoffmann-La Roche Ltd Business Overview
  10. 8.2.3 F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Product Portfolio
  12. 8.2.5 F. Hoffmann-La Roche Ltd Recent Developments
  13. 8.3 Eli Lilly and Co
  14. 8.3.1 Eli Lilly and Co Company Information
  15. 8.3.2 Eli Lilly and Co Business Overview
  16. 8.3.3 Eli Lilly and Co Oligodendroglioma Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly and Co Oligodendroglioma Treatment Product Portfolio
  18. 8.3.5 Eli Lilly and Co Recent Developments
  19. 8.4 Pfizer Inc
  20. 8.4.1 Pfizer Inc Company Information
  21. 8.4.2 Pfizer Inc Business Overview
  22. 8.4.3 Pfizer Inc Oligodendroglioma Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc Oligodendroglioma Treatment Product Portfolio
  24. 8.4.5 Pfizer Inc Recent Developments
  25. 8.5 Tocagen Inc
  26. 8.5.1 Tocagen Inc Company Information
  27. 8.5.2 Tocagen Inc Business Overview
  28. 8.5.3 Tocagen Inc Oligodendroglioma Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Tocagen Inc Oligodendroglioma Treatment Product Portfolio
  30. 8.5.5 Tocagen Inc Recent Developments
  31. 8.6 Northwest Biotherapeutics Inc
  32. 8.6.1 Northwest Biotherapeutics Inc Company Information
  33. 8.6.2 Northwest Biotherapeutics Inc Business Overview
  34. 8.6.3 Northwest Biotherapeutics Inc Oligodendroglioma Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Northwest Biotherapeutics Inc Oligodendroglioma Treatment Product Portfolio
  36. 8.6.5 Northwest Biotherapeutics Inc Recent Developments
  37. 8.7 Millennium Pharmaceuticals Inc
  38. 8.7.1 Millennium Pharmaceuticals Inc Company Information
  39. 8.7.2 Millennium Pharmaceuticals Inc Business Overview
  40. 8.7.3 Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Product Portfolio
  42. 8.7.5 Millennium Pharmaceuticals Inc Recent Developments
  43. 8.8 Leadiant Biosciences Inc
  44. 8.8.1 Leadiant Biosciences Inc Company Information
  45. 8.8.2 Leadiant Biosciences Inc Business Overview
  46. 8.8.3 Leadiant Biosciences Inc Oligodendroglioma Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Leadiant Biosciences Inc Oligodendroglioma Treatment Product Portfolio
  48. 8.8.5 Leadiant Biosciences Inc Recent Developments
  49. 8.9 Ipsen SA
  50. 8.9.1 Ipsen SA Company Information
  51. 8.9.2 Ipsen SA Business Overview
  52. 8.9.3 Ipsen SA Oligodendroglioma Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ipsen SA Oligodendroglioma Treatment Product Portfolio
  54. 8.9.5 Ipsen SA Recent Developments
  55. 8.10 Immatics Biotechnologies GmbH
  56. 8.10.1 Immatics Biotechnologies GmbH Company Information
  57. 8.10.2 Immatics Biotechnologies GmbH Business Overview
  58. 8.10.3 Immatics Biotechnologies GmbH Oligodendroglioma Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Immatics Biotechnologies GmbH Oligodendroglioma Treatment Product Portfolio
  60. 8.10.5 Immatics Biotechnologies GmbH Recent Developments
  61. 8.11 Celldex Therapeutics Inc
  62. 8.11.1 Celldex Therapeutics Inc Company Information
  63. 8.11.2 Celldex Therapeutics Inc Business Overview
  64. 8.11.3 Celldex Therapeutics Inc Oligodendroglioma Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Celldex Therapeutics Inc Oligodendroglioma Treatment Product Portfolio
  66. 8.11.5 Celldex Therapeutics Inc Recent Developments
  67. 8.12 Cavion LLC
  68. 8.12.1 Cavion LLC Company Information
  69. 8.12.2 Cavion LLC Business Overview
  70. 8.12.3 Cavion LLC Oligodendroglioma Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Cavion LLC Oligodendroglioma Treatment Product Portfolio
  72. 8.12.5 Cavion LLC Recent Developments
  73. 8.13 Bristol-Myers Squibb Co
  74. 8.13.1 Bristol-Myers Squibb Co Company Information
  75. 8.13.2 Bristol-Myers Squibb Co Business Overview
  76. 8.13.3 Bristol-Myers Squibb Co Oligodendroglioma Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bristol-Myers Squibb Co Oligodendroglioma Treatment Product Portfolio
  78. 8.13.5 Bristol-Myers Squibb Co Recent Developments
  79. 8.14 Boehringer Ingelheim GmbH
  80. 8.14.1 Boehringer Ingelheim GmbH Company Information
  81. 8.14.2 Boehringer Ingelheim GmbH Business Overview
  82. 8.14.3 Boehringer Ingelheim GmbH Oligodendroglioma Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Boehringer Ingelheim GmbH Oligodendroglioma Treatment Product Portfolio
  84. 8.14.5 Boehringer Ingelheim GmbH Recent Developments
  85. 8.15 AngioChem Inc
  86. 8.15.1 AngioChem Inc Company Information
  87. 8.15.2 AngioChem Inc Business Overview
  88. 8.15.3 AngioChem Inc Oligodendroglioma Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AngioChem Inc Oligodendroglioma Treatment Product Portfolio
  90. 8.15.5 AngioChem Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oligodendroglioma Treatment Value Chain Analysis
  2. 9.1.1 Oligodendroglioma Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oligodendroglioma Treatment Production Mode & Process
  6. 9.2 Oligodendroglioma Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oligodendroglioma Treatment Distributors
  9. 9.2.3 Oligodendroglioma Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst